CF
BCRX icon

Cantor Fitzgerald’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cantor Fitzgerald’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-106,307
Closed -$807K – 231
2025
Q3 		$807K Buy
106,307
+35,000
+49% +$291K 0.01% 241
2025
Q2 		$639K Buy
+71,307
New +$664K 0.01% 200

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cantor Fitzgerald's BCRX Position: Q4 2025 in Review

Cantor Fitzgerald sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 106,307 shares — an estimated $807K sold.

Cantor Fitzgerald first reported a position in BCRX in Q2 2025 and held it in 2 quarters. The position peaked at $807K in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Cantor Fitzgerald reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 106,307 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $807K.
  • Cantor Fitzgerald first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Cantor Fitzgerald's BioCryst Pharmaceuticals position peaked at $807K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.